company background image
FAE logo

Faes Farma BME:FAE Stock Report

Last Price

€3.02

Market Cap

€946.8m

7D

0.3%

1Y

-16.0%

Updated

23 Feb, 2024

Data

Company Financials +

Faes Farma, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Faes Farma
Historical stock prices
Current Share Price€3.02
52 Week High€3.67
52 Week Low€2.87
Beta0.50
1 Month Change-3.52%
3 Month Change-4.59%
1 Year Change-16.02%
3 Year Change-17.85%
5 Year Change-14.10%
Change since IPO197.37%

Recent News & Updates

Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Dec 18
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Dec 04
Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Recent updates

Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Dec 18
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Dec 04
Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Nov 24
Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

May 03
Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Sep 21
Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Is Faes Farma (BME:FAE) A Risky Investment?

Aug 03
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Jun 17
Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Is Faes Farma (BME:FAE) Using Too Much Debt?

Mar 27
Is Faes Farma (BME:FAE) Using Too Much Debt?

Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Dec 13
Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Nov 29
Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Is Faes Farma (BME:FAE) A Risky Investment?

Sep 21
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Is Faes Farma (BME:FAE) Using Too Much Debt?

May 01
Is Faes Farma (BME:FAE) Using Too Much Debt?

Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Apr 07
Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Mar 22
Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Mar 06
Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

Feb 22
Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Jan 16
I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Dec 08
Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Shareholder Returns

FAEES PharmaceuticalsES Market
7D0.3%-0.2%2.2%
1Y-16.0%22.2%8.6%

Return vs Industry: FAE underperformed the Spanish Pharmaceuticals industry which returned 20.9% over the past year.

Return vs Market: FAE underperformed the Spanish Market which returned 8.4% over the past year.

Price Volatility

Is FAE's price volatile compared to industry and market?
FAE volatility
FAE Average Weekly Movement1.8%
Pharmaceuticals Industry Average Movement3.4%
Market Average Movement3.0%
10% most volatile stocks in ES Market6.4%
10% least volatile stocks in ES Market0.7%

Stable Share Price: FAE has not had significant price volatility in the past 3 months.

Volatility Over Time: FAE's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19331,764n/ahttps://faesfarma.com

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.

Faes Farma, S.A. Fundamentals Summary

How do Faes Farma's earnings and revenue compare to its market cap?
FAE fundamental statistics
Market cap€946.77m
Earnings (TTM)€89.72m
Revenue (TTM)€471.66m

10.6x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FAE income statement (TTM)
Revenue€471.66m
Cost of Revenue€156.77m
Gross Profit€314.89m
Other Expenses€225.17m
Earnings€89.72m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 27, 2024

Earnings per share (EPS)0.29
Gross Margin66.76%
Net Profit Margin19.02%
Debt/Equity Ratio2.3%

How did FAE perform over the long term?

See historical performance and comparison

Dividends

5.2%

Current Dividend Yield

55%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.